title: Rituximab treatment of idiopathic membranous nephropathy.
abstract: Idiopathic membranous nephropathy is a common cause of nephrotic syndrome whose pathogenesis may involve B-cell functions. Rituximab is a monoclonal antibody that binds to the CD20 antigen on B cells thereby deleting them. We conducted an open-label pilot trial of rituximab treatment in 15 severely nephrotic patients with proteinuria refractory to angiotensin-converting enzyme inhibition and/or receptor blockade but with adequately controlled blood pressure. Rituximab was given 2 weeks apart and, at 6 months, patients who remained proteinuric but had recovered B-cell counts were given a second course of treatment. Proteinuria was significantly decreased by about half at 12 months. Of the 14 patients who completed follow-up, full remission was achieved in two and partial remission in six patients based upon the degree of proteinuria. Side effects were minor; however, we found no relationship between the response and number of B cells in the blood, CD20 cells in the kidney biopsy, degree of tubulointerstitial fibrosis, starting proteinuria or creatinine values. Rituximab appears effective in reducing proteinuria in some patients with idiopathic membranous nephropathy but prospective identification of responsive patients was not possible.
authors.affiliation: Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW, Rochester, MN 55901, USA. fervenza.fernando@mayo.edu
authors.forename: F C
authors.initials: FC
authors.lastname: Fervenza
authors.forename: F G
authors.initials: FG
authors.lastname: Cosio
authors.forename: S B
authors.initials: SB
authors.lastname: Erickson
authors.forename: U
authors.initials: U
authors.lastname: Specks
authors.forename: A M
authors.initials: AM
authors.lastname: Herzenberg
authors.forename: J J
authors.initials: JJ
authors.lastname: Dillon
authors.forename: N
authors.initials: N
authors.lastname: Leung
authors.forename: I M
authors.initials: IM
authors.lastname: Cohen
authors.forename: D N
authors.initials: DN
authors.lastname: Wochos
authors.forename: E
authors.initials: E
authors.lastname: Bergstralh
authors.forename: M
authors.initials: M
authors.lastname: Hladunewich
authors.forename: D C
authors.initials: DC
authors.lastname: Cattran
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001402:B-Lymphocytes / Q000276:immunology; D005260:Female; D015433:Glomerulonephritis, Membranous / Q000188:drug therapy*; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D007155:Immunologic Factors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011507:Proteinuria / Q000175:diagnosis; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007136:Immunoglobulins; D007155:Immunologic Factors; D000069283:Rituximab